News Sentiment

KYMR sentiment intelligence

Kymera Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 119.35 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 56

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+5.1% over one week, +38.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Law firm probes Kymera Therapeutics' officers for possible self-dealing harming shareholders

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction 5.1% Price confirming higher
Trend fit Trend active 38.4% over four weeks
Fair value 155.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 34
Negative 15

Relevance

Why the article matched

Direct first
Direct company coverage 56
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Moomoo 7
MT Newswires 4
Quartr 3
Simply Wall Street 3
Investing.com Canada 3
timothysykes.com 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 44
Earnings 11
Analyst action 7
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Pluang Direct company coverage

Law firm probes Kymera Therapeutics' officers for possible self-dealing harming shareholders

Kuehn Law, PLLC is investigating Kymera Therapeutics, Inc. officers and directors for potential breaches of fiduciary duties through self-dealing. This legal probe aims to secure damages and governance reforms for shareholders. The firm encourages long-term investors in Kymera to

Tone
Negative 14/100
Event
Regulatory and legal
Published
17 Jul 2026 21:11
Source
Pluang
PR Newswire Direct company coverage

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)

Purcell & Lefkowitz LLP has initiated a shareholder investigation into Kymera Therapeutics, Inc. (NASDAQ: KYMR) to determine if its directors breached their fiduciary duties regarding recent corporate actions. Shareholders of Kymera Therapeutics are encouraged to contact the law

Tone
Negative 28/100
Event
Regulatory and legal
Published
16 Jul 2026 15:41
Source
PR Newswire
GuruFocus Direct company coverage

KYMR Maintained by Mizuho -- Price Target Raised to $140

Mizuho has maintained an "Outperform" rating for Kymera Therapeutics (KYMR) and increased its price target from $120 to $140, reflecting confidence in the company's potential. Despite this positive outlook, GuruFocus indicates that KYMR is significantly overvalued at 385.4% above

Tone
Negative 40/100
Event
Analyst action
Published
16 Jul 2026 12:41
Source
GuruFocus
Quartr Direct company coverage

Kymera Therapeutics (KYMR) AGM 2024 Summary

This article summarizes Kymera Therapeutics' (KYMR) 2024 Annual General Meeting, highlighting the agenda, board and executive updates, and four shareholder proposals discussed. It also provides a quick overview of recent company events and clinical advancements, including progres

Tone
Positive 73/100
Event
Market update
Published
16 Jul 2026 10:41
Source
Quartr
Quartr Direct company coverage

Kymera Therapeutics (KYMR) 44th Annual J.P. Morgan Healthcare Conference Summary

Kymera Therapeutics (KYMR) presented its strategic vision and pipeline progress at the 44th Annual J.P. Morgan Healthcare Conference. The company is focused on developing novel oral drugs for immune-inflammatory diseases, aiming to expand access for 160 million patients and revol

Tone
Positive 70/100
Event
Market update
Published
16 Jul 2026 09:43
Source
Quartr
Quartr Direct company coverage

Kymera Therapeutics (KYMR) Jefferies London Healthcare Conference 2025 Summary

Kymera Therapeutics (KYMR) presented a summary of its strategic focus and pipeline at the Jefferies London Healthcare Conference 2025. The company is developing oral medicines using targeted protein degradation, primarily in immunology, with a strong focus on its STAT6 program fo

Tone
Positive 74/100
Event
Market update
Published
16 Jul 2026 09:41
Source
Quartr
Investing.com Nigeria Direct company coverage

Form 144 Kymera Therapeutics For: 13 July By Investing.com

This article from Investing.com reports on a Form 144 filing by Kymera Therapeutics, dated July 13. Form 144 is a notice of the intent to sell restricted securities without registration. The article itself is very brief, mainly serving as a headline for the filing.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 23:08
Source
Investing.com Nigeria
Bitget Direct company coverage

RBC Capital Markets has adjusted its investment rating for Kymera Therapeutics Inc., downgrading it from "outperform" to "sector perform."

RBC Capital Markets has downgraded its investment rating for Kymera Therapeutics Inc. from "outperform" to "sector perform." Despite the downgrade, the institution increased its target share price for Kymera from $106 to $115. The article includes a disclaimer stating that the co

Tone
Negative 39/100
Event
Analyst action
Published
13 Jul 2026 20:10
Source
Bitget
marketscreener.com Direct company coverage

RBC Downgrades Kymera Therapeutics to Sector Perform From Outperform, Lifts Price Target to $115 From $106, Keeps Speculative Risk

RBC has downgraded Kymera Therapeutics (KYMR) from Outperform to Sector Perform. Despite the downgrade, the firm increased its price target for Kymera Therapeutics to $115 from the previous $106, while maintaining a speculative risk assessment for the stock. This adjustment refle

Tone
Negative 39/100
Event
Analyst action
Published
13 Jul 2026 10:43
Source
marketscreener.com
Simply Wall Street Direct company coverage

Does Leadership Hire And Benchmark Additions Change The Bull Case For Kymera Therapeutics (KYMR)?

Kymera Therapeutics has appointed Elizabeth Laws as SVP and KT-621 Development Program Leader and been added to Russell value and small-cap benchmarks, which are significant operational and market-profile milestones. These developments, particularly Laws' experience with immunolo

Tone
Positive 60/100
Event
Market update
Published
10 Jul 2026 16:46
Source
Simply Wall Street
Investing.com Direct company coverage

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock

Nello Mainolfi, CEO of Kymera Therapeutics, sold $5.95 million worth of company stock after exercising options. The transaction involved 50,000 shares at $119.00 each, occurring when KYMR shares were near their 52-week high after a significant 175% return. This comes as the compa

Tone
Positive 63/100
Event
Market update
Published
08 Jul 2026 17:42
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Kymera Therapeutics Inc For: 7 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Kymera Therapeutics Inc, dated July 7th. It indicates a stock performance of -3.10% for KYMR. The article primarily serves as a placeholder for the Form 4 information, surrounded by general market data and news headli

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:39
Source
Investing.com Nigeria
Investing.com South Africa Direct company coverage

Kymera Therapeutics CEO Mainolfi sells $5.95m in stock By Investing.com

Kymera Therapeutics, Inc. CEO Nello Mainolfi sold 50,000 shares of common stock worth $5.95 million after exercising stock options. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed significant company advancements, including accelerated enrollment

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:10
Source
Investing.com South Africa
Simply Wall Street Direct company coverage

Kymera Therapeutics (KYMR) Following Faster KT 621 Trial Progress Still Looks Modestly Undervalued

Kymera Therapeutics (KYMR) has completed patient enrollment for its KT-621 trial ahead of schedule, accelerating the timeline for topline data. Despite recent strong share price performance and index inclusion, analysts suggest the stock is still modestly undervalued, with a cons

Tone
Positive 67/100
Event
Market update
Published
07 Jul 2026 11:10
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

Kymera Therapeutics has appointed Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws, formerly an immunology leader at Sanofi, will lead the global development strategy for KT-621, a first-in-class oral STAT6 degrader for immunological di

Tone
Positive 72/100
Event
Market update
Published
07 Jul 2026 11:10
Source
The Globe and Mail
Finviz Direct company coverage

KYMR - Kymera Therapeutics Inc Options

This article provides a detailed financial overview of Kymera Therapeutics Inc (KYMR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional o

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 16:10
Source
Finviz
Finviz Direct company coverage

KYMR - Kymera Therapeutics Inc Volatility & Greeks

This article provides a detailed financial snapshot of Kymera Therapeutics Inc (KYMR), listing key metrics such as market capitalization, sales, earnings per share, and various financial ratios. It also includes information on volatility, share performance over different periods,

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 13:39
Source
Finviz
Sahm Direct company coverage

Kymera Therapeutics (KYMR) Is Up 16.7% After KT-621 Trial Acceleration And Index Additions Has The Bull Case Changed?

Kymera Therapeutics (KYMR) has seen a 16.7% stock increase following the early completion of enrollment for its KT-621 Phase 2b trial, updated timelines for data and Phase 3 initiation, new Board Chairman Felix J. Baker, and inclusion in Russell indices. These developments accele

Tone
Positive 67/100
Event
Market update
Published
03 Jul 2026 04:40
Source
Sahm
Simply Wall Street Direct company coverage

Kymera Therapeutics (KYMR) Stock Looks Fully Priced After A 405% Run

Kymera Therapeutics (KYMR) stock has seen a 405% return over three years but appears expensive based on Simply Wall St’s valuation checks, scoring 1 out of 6. The article questions whether the recent surge and high valuation leave enough room for investors, given the remaining ri

Tone
Negative 32/100
Event
Market update
Published
03 Jul 2026 04:10
Source
Simply Wall Street